6 documents found, page 1 of 1
Allergen Immunotherapy in MASK‐Air Users in Real‐Life: Results of a Bayesian Mi...
Sousa‐Pinto, B; Azevedo, LF; Sá‐Sousa, A; Vieira, RJ; Amaral, R; Klimek, L; Czarlewski, W; Anto, JM; Bedbrook, A; Kvedariene, V; Ventura, MTBackground: Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. Objective: To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those rec...
Behavioural Patterns in Allergic Rhinitis Medication in Europe: A Study Using M...
Sousa‐Pinto, B; Sá‐Sousa, A; Vieira, RJ; Amaral, R; Klimek, L; Czarlewski, W; Antó, JM; Pfaar, O; Bedbrook, A; Kvedariene, V; Ventura, MT; Ansotegui, IJBackground: Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. Methods: We analysed 2015-20...
ARIA Digital Anamorphosis: Digital Transformation of Health and Care in Airway ...
Bousquet, J; Anto, JM; Bachert, C; Haahtela, T; Zuberbier, T; Czarlewski, W; Bedbrook, A; Bosnic-Anticevich, S; Walter Canonica, G; Cardona, V; Costa, EDigital anamorphosis is used to define a distorted image of health and care that may be viewed correctly using digital tools and strategies. MASK digital anamorphosis represents the process used by MASK to develop the digital transformation of health and care in rhinitis. It strengthens the ARIA change management strategy in the prevention and management of airway disease. The MASK strategy is based on validate...
New and repurposed drugs to treat multidrug- and extensively drug-resistant tub...
Silva, DR; Dalcolmo, M; Tiberi, S; Arbex, MA; Munoz-Torrico, M; Duarte, R; D'Ambrosio, L; Visca, D; Rendon, A; Gaga, M; Zumla, A; Migliori, GBMultidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respectively) continue to represent a challenge for clinicians and public health authorities. Unfortunately, although there have been encouraging reports of higher success rates, the overall rate of favorable outcomes of M/XDR-TB treatment is only 54%, or much lower when the spectrum of drug resistance is beyond that of XDR-TB. ...
Erratum to: Scaling up strategies of the chronic respiratory disease programme ...
Bousquet, J; Farrell, J; Crooks, G; Hellings, P; Bel, E H; Bewick, M; Chavannes, N H; de Sousa, J Correia; Cruz, A A; Haahtela, T; Joos, G; Khaltaev, N[This corrects the article DOI: 10.1186/s13601-016-0116-9.].
ARIA 2016: Care pathways implementing emerging technologies for predictive medi...
Bousquet, J; Hellings, PW; Agache, I; Bedbrook, A; Bachert, C; Bergmann, KC; Bewick, M; Bindslev-Jensen, C; Bosnic-Anticevitch, S; Bucca, C; Caimmi, DPThe Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and im...